Leveraging ARV Optimization Opportunities to Unlock National Cost Savings

This memo highlights the benefits, market considerations, and potential for savings of three ARV optimization opportunities.

1. Proactively switch eligible adult second-line patients on protease inhibitors to DTG-based regimens

2. Ensure transition of pediatric patients to appropriate optimal products as they age and grow

3. Move to larger, carton-less pack sizes to enable multi-month dispensing

• View the memo in English

• View the memo in French